Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Patch Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers

NCT02256930
View directory record Official record
Conditions
Healthy Volunteers
Interventions
M518101, M518101 Vehicle, Sodium lauryl sulfate, Saline
Drug · Other
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00304239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Metvix-PDT, Vehicle-PDT
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

NCT02650505
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204, LEO 43204 Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers

NCT00605956
View directory record Official record
Conditions
Head Lice
Interventions
NatrOVA Creme Rinse - 1%, NatrOVA Creme Rinse Vehicle Only, Blank Patch
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

NCT04155203
View directory record Official record
Conditions
Secondarily Infected Traumatic Skin Lesions
Interventions
Mupirocin Calcium, Vehicle
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Months and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

NCT05078827
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients

NCT03377803
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

NCT03210740
View directory record Official record
Conditions
Actinic Keratosis
Interventions
AM001 Cream, 7.5%, Vehicle Cream
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers

NCT02227069
View directory record Official record
Conditions
Healthy Volunteers
Interventions
M518101, M518101 Vehicle, sodium lauryl sulfate, saline
Drug · Other
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, Vehicle Spray
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 25, 2026, 7:34 PM EDT
Suspended Phase 3 Interventional

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

NCT07265479
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%, Vehicle Cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
3 Months to 23 Months
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Bryant, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

8-Week Atopic Dermatitis (AD) Treatment Study

NCT03386032
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Investigational OTC Cream, 0.05% Desonide, Placebo Cream
Drug · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
12 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Raleigh, North Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Results available

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

NCT01682811
View directory record Official record
Conditions
Neurofibromatoses
Interventions
Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 25, 2026, 7:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

NCT01541553
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Cryotherapy, Vehicle, Ingenol metabute
Procedure · Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
35
States / cities
Fremont, California • Oceanside, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519
View directory record Official record
Conditions
Psoriasis
Interventions
U0267, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Bioequivalence of Ethylenediamine Dihydrochloride Study

NCT01798589
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Ethylenediamine dihydrochloride allergen patch
Drug
Lead sponsor
Allerderm
Industry
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 25, 2026, 7:34 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

NCT02062073
View directory record Official record
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, 0.1% sodium lauryl sulfate, saline 0.9%, Vehicle Lotion
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Fluphenazine Hydrochloride for Psoriasis

NCT00929578
View directory record Official record
Conditions
Psoriasis
Interventions
Fluphenazine, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Cantharidin in Molluscum Contagiosum

NCT00667225
View directory record Official record
Conditions
Molluscum Contagiosum, Skin Disease
Interventions
cantharidin's vehicle, Cantharidin 0.7%
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 10 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 25, 2026, 7:34 PM EDT